Dr. Reddy's successfully completes Phase I study (IV route) of DRL_TC, a proposed biosimilar of tocilizumabp

Dr. Reddy's Laboratories Ltd. , a global pharmaceutical company, announced that its tocilizumab biosimilar candidate, DRL_TC, successfully met its primary and secondary endpoints in a Phase I study.

Related Keywords

United States ,Reddy Tocilizumab ,Tocilizumab Roactemra ,Tocilizumab Actemra ,Jayanth Sridhar ,Reddy Laboratories ,Reddy Laboratories Ltd ,Double Blind ,Comparative Pharmacokinetic ,Pharmacodynamic Study ,Reference Tocilizumab ,Intravenous Route ,Normal Healthy Male Volunteer ,Global Head ,Laboratories Limited ,Drreddyslaboratories ,Ine089a01023 ,Ardy ,Tocilizumab ,Biosimilarcandidate ,Phase1study ,